Skip to Main Content

Paper Details

Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma.
Oncologist
23
2021
CDKN2A, Erdheim-Chester disease, FDCS, FDCSs, Follicular Dendritic Cell Sarcoma, HS, HSs, Histiocytic, Histiocytic and Dendritic Cell, Histiocytic and Dendritic Cell Sarcomas, Histiocytic and dendritic cell neoplasms, IDCS, IDCSs, LCS, LCSs, Langerhans cell histiocytosis, Langerhans cell sarcomas, M group histiocytoses, M group histiocytosis, MAPK, MAPK pathway, Mitogen-activated protein kinase, NF-B, TP53, TP53 mutations, Tumor, cancer, cancer-related genes, follicular dendritic cell sarcomas, histiocytic sarcomas, interdigitating dendritic cell sarcomas, malignant histiocytic and dendritic cell neoplasms, malignant histiocytosis, monocytic, monocytic or dendritic cell lineage, patient, patients, secondary histiocytic sarcoma, tumor, tumors
Author NameAffiliation
Jonathan K KillianFoundation Medicine, Inc.
Jonathan K KillianFoundation Medicine, Inc.
Jeffrey S RossFoundation Medicine, Inc.
Jeffrey S RossState University of New York Upstate Medical University
Shakti H RamkissoonFoundation Medicine, Inc.
Shakti H RamkissoonWake Forest Comprehensive Cancer Center and Department of Pathology, Wake Forest School of Medicine
  • 1 - 6

Datasets

Release 1.2